medigraphic.com
ISSN 1561-3070 (Electronic)

2015, Number 1

<< Back Next >>

Rev Cub Oftal 2015; 28 (1)

Intravitreal bevacizumab vs. triamcinolone acetonide injection to treat macular edema secondary to branch retinal vein occlusion

Chiang RC, Rúa MR, Llanes DS, Toledo GY, Lapido PS, Baldoquín RW

Language: Spanish
References: 50
Page: 10-22
PDF size: 147.78 Kb.


ABSTRACT

Objective: to compare the results of the intravitreal treatment with bevacizumab and with triamcinolone acetonide in the macular edema secondary to branch retinal vein occlusion.
Methods: a prospective, interventional, random and comparative study was carried out in 34 patients. The first group (16 patients) received intravitreal triamcinolone acetonide injection whereas the second group (18 patients) had bevacizumab injection up to completing three doses in each group, followed by a third dose of macular grid. The initial dose was applied three months after the occurrence of edema and the final evaluation was made 12 months afterwards. Best corrected visual acuity (Snellen's chart), the macular thickness and complications were assessed.
Results: in the first group, the best corrected visual acuity increased from 0,29 (0,05-05) to 0,64 (0,05-1,0) whereas in the second group it went from 0,24 (0,05-05) to 0,66 (0,1-1,0).The macular thickness of 551,3 (346-967) microns of the first group improved when reaching 204,06 (112-449) microns and that of the second group went from 546,2 (283-1020) microns to 181,05 (112-312) microns. As to the complications, 25 % of patients of the first group experienced eye hypertension, and 12,5 % of patients in the same group had cataract progression.
Conclusions: intravitreal bevacizumab injection treatment of the macular edema secondary to branch retinal vein occlusion was better than that based on triamcinolone acetonide injection. The complications associated to bevacizumab treatment were fewer.


REFERENCES

  1. Scott IV. Macular edema associated with retinal vein occlusion. Retina Today. 2010:54-5.

  2. Rogers SL, McIntosh RL, et al. Natural history of branch retinal vein occlusion: Evidence–based systematic review. Ophthalmology. 2010;117(6):1094-101.

  3. Chan A, Leung LS. Critical appraisal of the clinical utility of the dexamethasone intravitreal implant (Ozurdex) for the treatment of macular edema related to branch retinal vein occlusion or central retinal vein occlusion. Clin Ophthalmol. 2011;5:1043-9.

  4. Shak GK. Treatment of Retinal Vein Occlusion. Individualized therapy is crucial to good patient outcomes. Retina Today [revista en Internet]. 2012 [cited 2012 abril 23];(3). Available in: http://www.bmctoday.net/retinatoday/2012/03/article.asp?f=treatmentof retinal-vein-occlusion

  5. Rogers S, Mepid RL. The prevalence of retinal vein occlusion pooled data from population studies from the United States, Europe, Asia and Australia. Ophthalmology. 2010;117(2):313-9.

  6. Haller JA, Brown DM. Evaluating and Integrating New Evidence in the Treatment of RVO. Retina Today [revista en Internet]. 2010 [cited 2012 abril 23];(10)Suppl. 1. Available in: http://www.bmctoday.net/retinatoday/2010/10/supplement/article.asp? f=e valuating-and -integrating-new-evidence-in-the-treatment-of-rvo

  7. Brown DM. New Directions in RVO Treatment. Retina Today [revista en Internet]. 2010 [cited 2012 abril 23];(4) Suppl. 1. Available in: http://www.bmctoday.net/retinatoday/2010 /04/supplement/article.asp?f=new-directions-in-rvo-treatment

  8. Ho AC, Ip MS. An Evidence-based Approach for RVO: Corticosteroids, Implants and Anti- VEGF Therapies. Retina Today [revista en Internet]. 2011 [cited 2012 abril 23];(6). Available in: http://www.bmctoday.net/retinatoday/2011/06/supplement/article.asp? f=a n-evidence -based-approach-for-rvocorticosteroids-implants-and-antivegftherapies

  9. Schutze C, Schmidt-Erfurt U. Imaging for BRVO and CRVO. Retina Today [revista en Internet]. 2011 [cited 2012 abril 23];(6). Available in: http://www.bmctoday.net/retinatoday/2011/06/article.asp?f=imagingforbrvo- and-crvo

  10. Rehak J, Rehak M. Branch retinal vein occlusion: pathogenesis, visual prognosis and treatment modalities. Cur Eye Res. 2008;33(2):111-31.

  11. Hariprasad SM. Combination therapy for RVO. Retina Today. 2010:67-76.

  12. Boyer DS. The pathophysiology of macular edema. Retina Today [revista en Internet]. 2011 [cited 2012 abril 23];9(Suppl. 1). Available in: http://www.bmctoday.net/retinatoday/2011/09/supplement/article.asp? f=the-pathophysiology-of-macular-edema

  13. Hidetaka N. Vitreous inflammatory factors and serous macular detachment in branch retinal vein occlusion. Retina. 2012;32:86-91.

  14. Cousins SW, Boyer DS. New and Emerging Treatment Paradigms for Macular Edema in Retinal Vein Occlusions and Diabetic Retinopathy. Retina Today [revista en Internet]. 2010 [cited 2012 abril 23];10. Available in: http://www.bmctoday.net/retinatoday/2010/10/supplement/article.asp? f=evaluating-and-integrating-new-evidence-in-thetreatment-of-rvo

  15. Holekamp NM, Ip MS. Point Counteroint Early vs Late Pharmacologic Therapy for RVO. Retina Today [revista en Internet]. 2010 [cited 2012 abril 23];(8). Available in: http://www.bmctoday.net/retinatoday/2010/08/article.asp? f=pointcounterpointearly-vs-late-pharmacologic-therapy-for-rvo

  16. Herrero-Vanrell R, Cardillo JA, Kuppermann BD. Clinical applications of the sustained-release dexamethasone implant for treatment of macular edema. Clin Ophthalmol. 2011;5:139-46.

  17. Scott IV, Vanveldhuisen PC. Baseline predictors of visual acuity and retinal thickness outcomes in patients with retinal vein occlusion: standard care versus Corticosteroid for retinal vein occlusion. Study Report 10. Ophthalmology. 2011;118(2):345-52.

  18. Haller JA, Bandello F. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema du to retinal vein occlusion. Ophthalmology. 2010;117(6):1134-46.

  19. Haller JA, Bandello F. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion, twelve-month study results. Ophthalmology. 2011;118(12):2453-60.

  20. Campochiaro PA, Heier JS. Ranibizumab for macular edema following Branch retinal vein occlusion: six month primary end point results of a phase III study. Ophthalmology. 2010;117(6):1102-12.

  21. Brown DM. Clinical Implications of the BRVO and CRUISE Trials. Retina Today. 2010:38-40.

  22. Kitchens J. Baseline predictors of the number of ranibizumab retreatment injections in the BRAVO study during months. Chicago: poster presented at: American Academy of Ophthalmology Annual Meeting; October 16-19, 2010.

  23. Cekic O. A comparison of three different intravitreal treatment modalities of macular edema due to branch retinal vein occlusion. Curr Eye Res. 2010;35(10):925-9.

  24. Guthoff R. Comparison of bevacizumab and triamcinolone for treatment of macular edema secondary to branch retinal vein occlusion in a pair-matched analysis. Ophthalmologica. 2010;224(5):319-24.

  25. Byun YJ. Intravitreal triamcinolone acetonide versus bevacizumab therapy for macular edema associated with branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2010;248(7):63-71.

  26. Yasushi S. Early change of central macular Thickness after intravitreous triamcinolone or bevacizumab in diabetic macular edema or retinal vein occlusion. Retina. 2011;31:290-7.

  27. Chen CH. Treatment of branch retinal vein occlusion induced macular edema in treatment-naive cases with a single intravitreal triamcinolone or bevacizumab injection. Chang Gung Med J. 2010;33(4):424-35.

  28. Kelkar AS. Comparison of single injection of intravitreal triamcinolone versus single injection of intravitreal bevacizumab in macular edema secondary to branch retinal vein occlusion with regard to chances in best correct visual acuity and central macular thickness in the short term. Ind J Ophthalmol. 2009;57(3):243-44.

  29. Kim JY. Comparison between intravitreal bevacizumab and triamcinolone for macular edema secondary to branch retinal vein occlusion. Kor J Ophthalmol. 2009;23(4):259-65.

  30. Hou J. Intravitral bevacizumab versus triamcinolone acetonide for macular edema due to branch retinal vein occlusion: a matched study. Chin Med J. 2009;122(22):2695-9.

  31. Chen KC. Intravitreal triamcinolone acetonide vs. bevacizumab for treatment of macular edema secondary to branch retinal vein occlusion. Eye. 2009;23:2023-33.

  32. Lutz HA, Martínez RP. Oclusiones venosas retinales. Rev Méd Clínica Las Condes. 2010;21(6)961-5.

  33. Battaglia Parodi M, Saviano S, Ravalico G. Grid laser treatment in macular branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 1999;237:1024-7.

  34. Gallemare RP, Wallsh J. Management of retinal vein occlusion: what the clinical trials tell us. Retina Today. 2013:64-67.

  35. Wu L, Evans T. Brach Retinal Vein Occlusion: Treatment and Medication. MEDSCAPE Articles; Feb 19, 2010.

  36. Morse LS, Modjjtahedi S. Use of Intravitreal Steroids in the Clinic. Retina Today [revista en Internet]. 2010 [cited 2012 abril 23];(6)Suppl. 1. Available in: http://www.bmctoday.net/retinatoday/2010/06/supplement/article.asp? f=u se-of-intravitreal-steroids-in-the-clinic

  37. Oakley RH, Cidlowski JA. Evolving Science: The Pharmacology of Steroids. Retina Today [revista en Internet]. 2010 [cited 2012 abril 23];(5)Suppl. 1. Available in: http://www.bmctoday.net/retinatoday/2010/06/supplement/

  38. The SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: the Standard Care vs. Corticosteroid for Retinal Vein Occlusion (SCORE) Study Report 6. Arch Ophthalmol. 2009;127(9):1115-28.

  39. Benson WB. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion. Evidence-Based Ophthalmology. 2010;11(1):22-3.

  40. Campochiaro PA, Hafiz G, Shah SM, Nguyen QD, Ying H, Do DV, et al. Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator. Mol Ther. 2008;16(4):791-9.

  41. Pai SA, Shetty R, Vijayan PB, Venkatasubramaniam G, Yadav NK, Shetty BK, et al. Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion. Am J Ophthalmol. 2007;143(4):601-6.

  42. Kim JY, Park SP. Comparison Between Intravitreal Bevacizumab and Triamcinolone for Macular Edema Secondary to Branch Retinal Vein Occlusion. Korean J Ophthalmol. 2009;23(4):259-65.

  43. Adelman RA, Zheng Q, Mayer HR. Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections. J Ocul Pharmacol Ther. 2010 Feb;26(1):105-10.

  44. Yepremyan M, Wertz FD, Tivnan T, Eversman L, Marx JL. Early treatment of cystoid macular edema secondary to branch retinal vein occlusion with intravitreal triamcinolone acetonide. Ophthalmic Surg Lasers Imag. 2005;36(1):30-6.

  45. Jaissle GB, Leitritz M, Gelisken F, Ziemssen F, Bartz-Schmidt KU, Szurman P. Oneyear results after intravitreal bevacizumab therapy for macular edema secondary to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2009;247(1):27-33.

  46. Rabena MD, Pieramici DJ, Castellarin AA, Nasir MA, Avery RL. Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina. 2007;27(4):419-25.

  47. Hayreh SS. Hemicentral retinal vein occlusion: Natural history of visual outcome. Retina. 2012;32(1):68-76.

  48. Noma H. Influence of ischemia on visual function in patients with branch retinal vein occlusion and macular edema. Clin Ophthalmol. 2011;5:679-85.

  49. Jaulim A, Badia A. Branch retinal vein occlusion: epidemiology, pathogenesis, risk factors, clinical features, diagnosis and complications. An Update of the Literature. Retina; 2013;13(5):901-10.

  50. Shukla D, Behera UC. Serous macular detachment as a predictor of resolution of macular edema with intravitreal triamcinolone injection. Ophthalmic Surg Lasers Imaging. 2009;40:115-9.




2020     |     www.medigraphic.com